Navigation Links
Data published in PNAS show antibodies can be made 10 times more toxic to cancer cells

Engineering the "Fc" region of monoclonal antibodies (mAbs) increases their toxicity to cancer cells, potentially improving the utility of targeted cancer therapies, according to research conducted at Xencor, which will be published in the March 14 print issue of the Proceedings of the National Academy of Sciences (PNAS).

Monoclonal antibodies have important advantages over chemotherapy and small molecule drug treatments for cancer, such as their specificity in targeting tumor cells and low toxicity. There are currently eight approved anticancer antibody products on the market today and many more are in development. Unfortunately, many marketed treatments lack the desired potency against tumor cells, providing only incremental improvements in therapeutic success, and many development-stage antibodies fail in clinical trials due to lack of demonstrated efficacy.

Scientists at Xencor, a biotherapeutics company developing protein and antibody therapeutics, said the changes it made to the antibody Fc regions increased antibody effector functions such as activation of immune cells for tumor lysis, called Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), by more than two orders of magnitude. Studies conducted in in vivo models demonstrated that these antibodies were greater than ten times more toxic to target cells. The enhanced antibodies also were able to kill tumor cells that are typically "invisible" to other antibodies because they express low levels of target antigen.

"While antibodies such as Genentech's Rituxan are well known for their role in the treatment of cancer, many other promising antibodies are sub-optimal for use as therapeutics. They just aren't powerful enough," said Bassil Dahiyat, Ph.D., President and CEO of Xencor. "The work we published in PNAS shows that specific changes to the Fc regions of antibodies have the potential to greatly improve the effectiveness of next-generation antibody therapeutics, and may mean that many more antibodies can be used in the treatment of cancer than ever before."

Xencor's Fc variants were engineered using the company's XmAbTM technology, which couples computational design algorithms with high-throughput screening to rationally design the antibody constant region. The Fc portion of the constant region of the antibody has been shown in previous studies to be responsible for mediating antibody-dependent cell-mediated cytotoxicity and has been the target of Xencor's XmAb technology. Xencor has leveraged its XmAb technology to develop therapeutic antibodies, for which it plans to begin clinical testing next year.

"We've already applied the XmAb technology used in this research to generate a suite of patented Fc antibody variants that have optimized antibody-Fc receptor affinity, which translate into increased effector functions and improved cell cytotoxicity. These can be used to enhance the potency of nearly any antibody under development today," Dahiyat added.


'"/>

Source:Porter Novelli, Life Sciences


Related biology news :

1. Comprehensive biodefense text published
2. First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology
3. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
4. Combating anthrax: Results of study published this month as researchers look for a better vaccine
5. Genomic comparison of lactic acid bacteria published
6. The first tree genome is published: Poplar holds promise as renewable bioenergy resource
7. Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned
8. Horse antibodies against the bird flu virus H5N1 are effective as treatment in mice
9. Mice studies illustrate potential of chimp/human antibodies to protect against smallpox
10. GlycoFi announces the first production of antibodies with human glycosylation in yeast
11. Report calls for improved monoclonal antibodies against solid tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... ... 23, 2017 , ... BellBrook Labs is formalizing a significant ... of biochemical analyses critical for Lead Discovery. The company’s Lead Discovery Services ... including inhibitor potency and selectivity, mechanism of action, and inhibitor residence times on ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life Sciences ... line of oncolytic vaccinia viruses for virotherapy research. ... part of Genelux,s proprietary, vaccinia virus-based technology platform ... to enter into a partnership with Genelux to ... vaccinia viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... , ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, NC ... GGI's mission is to advance global health and highlight the greater good of clinical ... each clinical trial volunteer. The vision of GGI is to serve as a philanthropic ...
(Date:2/22/2017)... -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused ... for companion animals, will host a live conference call on ... financial results from the fourth quarter and full year ended ... may access the audio webcast or use the ... ...
Breaking Biology Technology: